Retatrutide
Retatrutide (GLP-1/GIP/Glucagon Triple Agonist)
A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 data shows up to 24% weight loss — potentially superior to all approved agents.
Retatrutide is not approved by the FDA for human use. It is sold strictly for research purposes only and is not intended for human consumption, diagnosis, treatment, or prevention of any disease or condition. Purchase and use is entirely at your own risk.
Sourcing for research purposes?
View at Ascension Peptides →What it is
Retatrutide is an investigational peptide developed by Eli Lilly that simultaneously activates three receptors: GLP-1, GIP, and glucagon. This triple mechanism is designed to combine the appetite suppression of GLP-1, the metabolic enhancement of GIP, and the energy expenditure increase from glucagon receptor activation.
As of publication, retatrutide has not received FDA approval but has completed Phase 2 trials with striking results. Phase 3 trials are underway.
What research shows
- Up to 24.2% mean body weight reduction at 48 weeks (Phase 2, highest dose group)
- Dose-dependent weight loss across all dose groups studied
- Significant improvements in cardiometabolic markers
- Potentially the most effective weight loss agent studied in trials to date
- Phase 3 trials ongoing — results pending
What remains unknown
- FDA approval status — Phase 3 data not yet available at time of writing
- Long-term safety profile — Phase 2 trials are relatively short
- Head-to-head comparison with tirzepatide under equivalent conditions
- Durability of weight loss after discontinuation
Administration basics
Common use cases
Investigational weight management. Not yet commercially available.
Half-life
~6 days (weekly dosing in trials).
Administration
Subcutaneous injection once weekly (in trials).
Source this compound
Looking for Retatrutide?
Ascension Peptides is a third-party research compound vendor. We link to them as an affiliate — if you purchase through our link we may earn a commission at no cost to you. All compounds are sold for research purposes only and are not intended for human use.
View at Ascension PeptidesResearch Protocols & Common Usage
Doses used in research
- Phase 2 trials studied doses from 1mg to 12mg/week subcutaneously
- 8mg and 12mg/week showed the highest weight loss in trials
- Titration protocols were used starting at 1–2mg/week
Administration routes studied
Typical protocol duration
Phase 2 trials ran 48 weeks. As a research compound, long-term human safety data is not yet available.
Common stacking protocols
- Retatrutide has not been formally studied in combination with other compounds
- Should not be combined with other GLP-1, GIP, or glucagon receptor agonists
Contraindications & combinations to avoid
- Not FDA-approved — research compound status means full human safety profile is not established
- Expected to carry same class warnings as semaglutide (MTC, MEN2, pancreatitis) based on shared GLP-1 mechanism
- Should not be combined with any other incretin therapy
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with Retatrutide and what to avoid.
Track your Retatrutide protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the Retatrutide page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.